RxDoctor Payments Data

Jehan Abdulsattar, MD

Anatomic Pathology · Shreveport, LANPI 1124448584

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $381, 3.1 times the $125 reported in 2022.

$931in general payments, 2019–2025

Across 40 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$215
  • Tempus AI, Inc$154
  • Janssen Scientific Affairs, LLC$125
  • Stemline Therapeutics Inc.$107
  • Apellis Pharmaceuticals, Inc.$49
  • Novartis$43
  • plus $237 from 10 others

What the payments were for

  • Food & beverage$931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few anatomic pathology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$26,938
Medicare patients
247
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →